Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 14,500 shares, a decrease of 68.0% from the March 31st total of 45,300 shares. Based on an average trading volume of 55,500 shares, the short-interest ratio is currently 0.3 days. Approximately 0.3% of the shares of the stock are sold short.

Alzamend Neuro Stock Performance

NASDAQ:ALZN opened at $0.70 on Friday. Alzamend Neuro has a 1 year low of $0.65 and a 1 year high of $11.91. The stock has a fifty day moving average price of $0.92 and a two-hundred day moving average price of $1.23. The stock has a market capitalization of $4.81 million, a price-to-earnings ratio of -0.71 and a beta of 0.02.

Alzamend Neuro (NASDAQ:ALZN) last issued its earnings results on Monday, March 25th. The company reported ($0.38) earnings per share for the quarter.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.